Polycystic Ovary Syndrome: A Hidden Risk for Metabolic and Cardiovascular Diseases?
METHODOLOGY:
- PCOS features intrinsic insulin resistance, regardless of body weight, potentially due to increased liver fat deposition, which may exacerbate adverse clinical outcomes.
- To understand the association between PCOS and the risk for cardiometabolic diseases, cancer, and dementia, researchers conducted a prospective study including 1008 women with PCOS and 5017 age- and body mass index–matched control participants without PCOS using data from the UK Biobank.
- Liver, cardiac, and brain health were assessed using multiorgan MRI, and the impact of PCOS phenotypes (hyperandrogenic and normoandrogenic) on disease risk was evaluated.
- The primary outcomes were the prevalence and incidence of metabolic diseases (T2D, MASLD, and obstructive sleep apnea), all-cause CVD and CVD components, hormone-dependent cancers, and dementia.
TAKEAWAY:
- Incidence rates of T2D (adjusted hazard ratio [aHR], 1.47) and all-cause CVD (aHR, 1.76) were higher in women with PCOS than in control participants.
- Compared with control participants, women with PCOS had a higher prevalence of hepatic steatosis (P = .02) and greater hepatic fibroinflammation (P ≤ .01).
- PCOS was significantly associated with the incidence of all-cause CVD in normoandrogenic PCOS (aHR, 1.90) but not in hyperandrogenic PCOS. However, hyperandrogenic PCOS was associated with greater liver fat content and hepatic fibroinflammation than normoandrogenic PCOS (P < .01).
- The incidence of cancer or dementia was not significantly different among women with PCOS and control participants.
https://www.medscape.com/viewarticle/polycystic-ovary-syndrome-hidden-risk-metabolic-and-2024a1000ffe